AURA · Aura Biosciences, Inc.

On May 4, 2026, Aura Biosciences entered into an underwriting agreement with Leerink Partners, TD Securities, and Evercore Group for an underwritten public offering. The offering comprised 39,591,000 shares of common stock at $6.00 per share and pre-funded warrants to purchase 3,800,000 shares at $5.99999 per warrant. The underwriters exercised their option to purchase an additional 6,508,650 shares in full. The offering closed on May 5, 2026, generating net proceeds of approximately $280.8 million after underwriting discounts and estimated expenses. The company plans to use $241.8 million of the net proceeds, together with existing cash, to advance its clinical programs, including early choroidal melanoma and registration-enabling activities for bel-sar, and for general corporate purposes. Additionally, $39.0 million will be used to repurchase 6,922,870 shares of common stock held by Matrix Capital Management Master Fund, LP at $5.64 per share, the same price paid by underwriters. The company believes the net proceeds, combined with existing cash, will fund operations into the second half of 2028. The underwriting agreement contains customary representations, warranties, and indemnification obligations. The legal opinion from Goodwin Procter LLP confirms the validity of the securities issued.